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Received October 5, 2010; accepted December 17, 2010AbstractBackground: To investigate recurrence rates and fertility outcomes of patients with borderline ovarian tumors (BOTs) treated with fertility-
sparing surgery.
Methods: This was a retrospective study. All women with BOTs from 2000 to 2006 were evaluated. Clinical outcomes were compared among
groups that underwent radical, unilateral salpingo-oophorectomy, or ovarian cystectomy. The effects of clinical characteristics on recurrence
were analyzed by independent t test, chi-square test, and Cox proportional hazard model.
Results: After a mean follow-up period of 56.5 months, all 61 patients were alive. Seven (11.5%) had developed disease recurrence, and all were
in the fertility-sparing group. Of these, five were in the cystectomy-only group and two in the unilateral salpingo-oophorectomy group. There
was significant difference in tumor recurrence rates between the two groups (hazard ratio: 0.26, 95% confidence interval: 0.11e0.61). Nine
pregnancies were achieved in six women, resulting in five deliveries
Conclusion: Fertility-sparing surgery is an acceptable and safe option for women with BOTs who wish to preserve fertility. Unilateral salpingo-
oophorectomy must be considered as the first choice.
Copyright  2011 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
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1. Introduction Because of BOT’s benign behavior, surgical managementBorderline ovarian tumors (BOTs) account for 10e15% of
all ovarian tumors. They are characterized by a degree of cellular
proliferation and nuclear atypia in the absence of stromal
invasion.1 Compared with invasive ovarian cancer, they are
typically present in a younger age group, mostly diagnosed at an
earlier stage, and result in excellent prognosis. The five-year
overall survival rate for early-stage disease is approximately
98% and for more advanced diseases, varies between 86 and
92%.2* Corresponding author. Dr. Ming-Shyen Yen, Department of Obstetrics and
Gynecology, Taipei Veterans General Hospital, 201, Section 2, Shih-Pai Road,
Taipei 112, Taiwan, ROC.
E-mail address: drtsai0627@yahoo.com.tw (M.-S. Yen).
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doi:10.1016/j.jcma.2011.04.003has evolved towards a more conservative and minimally
invasive approach, allowing women to maintain fertility and
childbearing potentials. Recent reports on the use of fertility-
sparing surgery in women with BOTs suggested that it is
well tolerated and is the best option to preserve fertility
capacity in young women.3,4 After fertility-sparing surgery,
pregnancy outcomes are promising and most pregnancies are
achieved spontaneously. However, as important as the fertility
issue is whether morbidity caused by radical surgery can be
removed, or whether a more conservative approach is a safer
alternative in terms of cancer prognosis.
Although several studies indicate the safety of fertility-
sparing surgery, there remains a lot of debate regarding the
extent of the surgical procedure. Conservative surgery consists
of doing unilateral salpingo-oophorectomy or cystectomy forhinese Medical Association. All rights reserved.
Disease-free months 
Cu
m
ul
at
ive
 s
ur
viv
al
 
Surgical procedure
Ovarian cystectomy
Ovarian cystectomy-
censored
USO
USO-censored
p < 0.001
Fig. 1. Disease-free survival by surgical procedures. The statistical differences
of univariate KaplaneMeier curves were calculated using log-rank compari-
sons. USO ¼ unilateral salpingo-oophorectomy.
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provide a better chance of preserving fertility, however, the
risk of leaving malignant cells behind inadvertently may be
increasing. Although the question of fertility-sparing surgery
has been addressed in many studies, only limited published
data are available on the safety and outcome of treatment by
cystectomy only.
Our study evaluated the outcome of BOTs in patients
treated by fertility-sparing surgery through the recurrence rate
and pregnancy outcomes. We also compared the outcome of
patients treated by cystectomy only with that of patients
treated by unilateral salpingo-oophorectomy.
2. Methods
The study group was composed of 61 patients with BOTs
treated in Taipei Veterans General Hospital from 2000 to 2006.
Collected data included in patient and out patient records,
surgical notes, pathology reports, and clinical outcomes,
retrospectively. All the patients had undergone laparotomy,
and they were grouped according to the different surgical
approaches.
Fertility-sparing surgery was defined as any procedure that
left the uterus and at least some ovarian tissue intact. Radical
surgery was defined as optimal debulking surgery, including
total hysterectomy, bilateral salpingo-oophorectomy, omen-
tectomy, retroperitoneal pelvic lymph node dissection and
radical dissection of tumors. The criterion of disease staging
was according to the 1988 International Federation of Gyne-
cology and Obstetrics criteria, based on surgical notes and
pathology reports. Follow-up was performed by clinical
assessment, CA 125 testing, and trans-vaginal sonography
every three months for two years and every six months up to
five years from diagnosis, and then annually.
Tumor recurrence rate, disease-free survival, site of recur-
rence, and histology type were evaluated. Survival curves and
rates were calculated using the KaplaneMeier method.
Differences in survival were assessed using the log-rank test
for categorical factors and Cox proportional hazards model for
continuous factors. Multivariate analysis was performed using
Cox proportional hazards model by forward selection to
determine survival benefit, after adjusting for favorable prog-
nostic variables (Fig. 1).
Frequency distributions were compared using Chi-squared
and Fisher’s exact tests, whereas the mean and median
values among groups were compared using Student’s t-test and
the ManneWhitney U-test. A p value < 0.05 in a two-sided
test was considered statistically significant. All analysis used
the SPSS software for Windows (version 17.0; SPSS Inc.,
Chicago, IL).
3. Results
Of the 61 BOT patients, 30 underwent radical surgery and
31 had fertility-sparing surgery to preserve the uterus and
unilateral/bilateral ovaries (Table 1). Among them, 41 (67.2%)
were stage Ia, 4 (6.6%) stage Ib, 12 (19.7%) stage Ic, 1 (1.6%)stage II, and 3 (4.9%) stage III. Patients’ age was significantly
younger in the fertility-sparing surgery group than in the
radical surgery group ( p ¼ 0.003). Other characteristics,
including disease stage, tumor size, tumor histology, and
serum CA 125, did not differ significantly between the two
surgery groups. However, within a mean period of
56.5 months (range, 12e103 months), seven (11.5%) of 61
women developed disease recurrence, and all were in the
fertility-sparing group. The recurrence rate was significantly
higher in the fertility-sparing group than in the radical group
(22.6% vs. 0%, p ¼ 0.006).
Among 7 cases with disease recurrence, five were in the
cystectomy-only group and two from the USO group. The
median time for recurrence was 25.1 months (range, 10e56
months) (Table 2). Two cases developed invasive carcinomas,
whereas the other five had recurrent borderline tumors. The
most common site of recurrence was the remaining ovarian
tissue: 3 in the ipsilateral ovary, 3 in the contralateral ovary,
and 1 in the both ovaries. Three patients underwent second-
round fertility-sparing surgery whereas the other four were
successfully treated with complete staging surgery. All of the
patients with recurrences were alive and disease-free at a mean
follow-up of 36 months from diagnosis of recurrence.
Univariate analysis showed the disease-free survival in the
fertility-sparing group was significantly influenced by surgical
type ( p ¼ 0.005) and intra-operative tumor rupture
( p ¼ 0.026) (Table 3). Disease-free survival was not signifi-
cantly influenced by age, parity, International federation of
obstetrics and gynecology stage, lymphadenectomy, tumor
size, and pre-operative serum CA 125 level. Prognostic factors
in the multivariate analysis showed that only surgical type was
an independent prognostic factor for disease-free survival
[USO vs. cystectomy, hazard ratio (HR): 0.26 95% confidence
interval (CI), 0.11e0.61] (Table 4).
After treatment of the borderline tumor in the fertility-
sparing group, 18 (58%) patients had regular menstruation, 4
Table 1
Patients’ characteristics (n ¼ 61)
Characteristics Radical surgery Fertility-sparing surgery p
Numbers of patients 30 31
Age mean  SD (yr) 53.5  15.70 40.7  16.50 0.003*
Parity, n (%) p ¼ 0 5 (16.7%) 17 (54.8%) 0.002*
p S 1 25 (83.3%) 14 (45.2%)
Stage, n (%) Ia 18 (60%) 23 (74.2%) 0.242
Ib, Ic, II, III 12 (40%) 8 (25.8%)
Lymphadnectomy, n (%) Performed 29 (96.7%) 15 (48.4%) <0.001*
Not performed 1 ( 3.3%) 16 (51.6%)
Tumor size (cm) <10 cm 11 (36.7%) 14 (45.2%) 0.504
S10 cm 19 (63.3%) 17 (54.8%)
Frozen pathology, n (%) Do 27 (90%) 22 (71.0%) 0.064
Not do 3 (10%) 9 (29.0%)
Histology, n (%) Serous 8 (26.7%) 6 (19.4%) 0.935
Mucinous 21 (70%) 22 (70.9%)
Others 1 ( 3.3%) 3 ( 9.7%)
CA 125 (U/mL) &35 17 (56.7%) 13 (41.9%) 0.223
>35 13 (43.3%) 18 (58.1%)
Recurrence, n (%) 0 (0%) 7 (22.6%) 0.006*
Data are mean  standard deviation or case numbers. Numbers in parentheses refer to the percentage of the total number of patients in each group.
*A p value < 0.05 is statistically significant.
CA ¼ cancer antigen; SD ¼ standard deviation.
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treated by complete staging surgery. Nine pregnancies were
achieved in six women, resulting in five deliveries, including 2
in the cystectomy-only group and 3 in the USO group.
4. Discussion
BOTs are mostly present in a younger age group and
therefore, fertility sparing is an important and inevitable issue.
The generally benign behavior and favorable prognosis of
BOTs allows for more conservative management. In our study,
we demonstrated that unilateral salpingo-oophorectomy
should be considered as the first choice of fertility-sparing
treatment for younger women with BOTs who wish to
preserve fertility. Although the higher risk of local relapses is
found, it is not associated with decreased overall survival.
Ovarian cystectomy should be reserved for patients with
a previous history of unilateral adnexectectomy or bilateralTable 2
Characteristics of patients with recurrent disease
Case Age FIGO
stage
Histology Rupture
during
operation
LND Surgical
procedure
Site of recurrence Histo
1 23 Ic Mucinous Yes No Cystectomy Ipsilateral ovary Bord
2 37 Ic Serous Yes Yes Cystectomy Ipsilateral ovary Bord
3 38 Ic Clear Yes Yes Cystectomy Contralateral ovary Bord
4 32 Ia Mucinous No Yes Cystectomy Bilateral ovary Endo
and e
5 58 Ic Mucinous Yes No USO Contralateral ovary Muc
canc
6 33 Ia Mucinous No No USO Contralateral ovary Bord
7 31 Ic Mucinous Yes No Cystectomy Ipisilateral ovary Bord
FIGO ¼ International federation of obstetrics and gynecology; LND ¼ lymph
oophorectomy.ovarian tumors, and is advocated in incidental histologic
discovery of BOTs.
Numerous studies have demonstrated the safety and
possibility of conservative surgery.4 In literature, relapse is
generally increased if a fertility-sparing approach is chosen,
with numbers that vary between 0 and 25% compared with
w5% in women with radical surgery.7,8 Nonetheless, favor-
able prognosis and comparable survival rates are reported for
women who undergo either fertility-sparing or radical
surgery.9 This is consistent with our results. In our study, the
recurrence rate was 22.6% of women who had undergone
fertility-sparing surgery, and all the patients with recurrences
were alive and disease-free after treatment at a mean follow-up
of 36 months from diagnosis of recurrence. Therefore, we
suggest that fertility-sparing surgery is safe and possible to
perform for women with BOTs.
Lately, although management has changed from radical
surgery to a more conservative therapy for early stage BOTs,logy at recurrence Treatment at recurrence PFS (M) Pregnancy Status
erline Oophorectomy þ LND 56 Yes Alive
erline Oophorectomy þ LND 12 Regular mense Alive
erline Complete staging surgery 27 e Alive
metrioid ovarian
ndometrial cancer
Complete staging surgery 10 e Alive
ionus ovarian
er
Complete staging surgery 36 e Alive
erline Complete staging surgery 22 e Alive
erline Oophorecotmy þ LND 13 Regular mense Alive
adenectomy; PFS ¼ progression-free survival; USO ¼ unilateral salpingo-
Table 3
Factors associated with disease-free survival after fertility-sparing surgery
(n ¼ 31)
Characteristics n Recurrence Median
Survival,
months
HR 95% CI p
LLeUL
Surgery type
Oophorectomy 24 2 89.1 1
Cystectomy 7 5 36.3 10.73 2.07e55.60 0.005*
Age
>35 yr 14 3 78.0 1
&35 yr 17 4 58.9 1.20 0.27e5.35 0.816
Parity
¼0 17 6 90.5 1
S1 14 1 59.1 0.16 0.02e1.35 0.093
FIGO stage
Stage Ib, Ic, II, III 8 1 86.0 1
Stage ¼ Ia 23 6 73.9 2.46 0.30e20.47 0.405
Lymphadnectomy
Not performed 16 4 75.8 1
Performed 15 3 69.3 0.86 0.19e3.85 0.842
Tumor rupture
No 21 2 88.0 1
Yes 10 5 59.3 5.32 1.03e27.5 0.026*
Tumor size
&10 cm 14 5 66.3 1
>10 cm 17 2 86.1 0.30 0.06e1.53 0.146
Serum CA 125 level
>35 mg/dL 14 3 69.4 1
&35 mg/dL 17 4 75.3 2.05 0.40e10.60 0.391
Frozen pathology
Performed 21 5 76.1 1
Not performed 10 2 78.7 0.286 0.03e2.39 0.248
*A p value < 0.05 is statistically significant.
CA ¼ cancer antigen; CI ¼ confidence interval; FIGO ¼ International
federation of obstetrics and gynecology; HR ¼ hazard ratio; LL ¼ lower limit;
OR ¼ odds ratio; UL ¼ upper limit.
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surgical procedure. Ovarian cystectomy provides more chan-
ces of preserving fertility compared with unilateral salpingo-
oophorectomy because of the removal of less ovarian tissue.
However, ovarian cystectomy also elevates the risk of inad-
vertently leaving behind some malignant cells, as well as cyst
rupture and intra-abdominal spillage. Yinon et al., in a single-
center retrospective study of 62 patients treated conservatively
with cystectomy (n ¼ 22) and USO (n ¼ 40) revealed no
significant difference between the two groups in meanTable 4
Cox multivariate regression analysis
Model covariate HR 95% CI p (Cox model)
LL UL
Surgery type 0.26 0.11 0.61 0.002*
FIGO stage 3.92 0.42 36.73 0.232
Lymphadnectomy 1.23 0.23 6.59 0.808
*A p value < 0.05 is statistically significant.
CI ¼ confidence interval; FIGO ¼ International federation of obstetrics and
gynecology; HR ¼ hazard ratio; LL ¼ lower limit; UL ¼ upper limit.recurrence rate (22.7% and 27.5%, respectively, p ¼ 0.8).10
This did not change when analyzed according to tumor
histology type. In contrast, the study by Morice et al. showed
higher recurrence rates in cystectomy than USO (36.3% vs.
15.1%, p < 0.01).11 However, such management indeed offers
even patients with advanced disease the chance to have
spontaneous pregnancy. In our study, there was also a signifi-
cantly higher relapse rate (5/7, 71.4%) in the cystectomy
group compared with the USO group (HR 10.725, 95% CI
2.07e55.60, p ¼ 0.005). Recurrence was relatively related to
local residual tumor after cystectomy rather than tumor
localization in the other ovary. Furthermore, cystectomy
resulted in cyst rupture and intra-abdominal spillage in 70% of
the study patients, which is associated with a significant
increase in local recurrence (HR: 5.32, 95% CI 1.03e27.5,
p ¼ 0.026). De Iaco et al. reported compatible results of the
incidence of intra-operative rupture.12 In a large French
retrospective study published by Poncelet et al. on women
diagnosed with early stage BOTs, patients who underwent
cystectomy had higher rates of intra-operative cyst rupture and
more recurrences compared with women who had unilateral or
bilateral oophorecotmy.13 A study by Vergote et al. clearly
demonstrated that rupture of an ovarian cyst is one of the most
important prognostic factors of disease-free survival in Stage I
invasive ovarian cancer.14 Although there are no prospective
studies in BOT patients that address this issue, spilling should
be avoided until otherwise confirmed. This suggests that
ovarian cystectomy should be considered only for women with
one ovary or with bilateral tumors who wish to preserve their
childbearing potential. It is recommended that unilateral
salpingo-oophorectomy may provide a safe therapeutic alter-
native for BOT in women wishing to preserve fertility.
In this study, there were nine pregnancies in six women,
resulting in five deliveries, including two in the cystectomy-
only group and three in the USO group. After treatment of
the borderline tumor in the fertility-sparing group, 18 (58%)
patients had regular menstruation. The reported spontaneous
fertility rates after conservative treatment of BOT vary
between 32 and 65%.7,15,16 The disease does not affect the
gestation or the follow-up period after the pregnancy. There-
fore, it is worthy for women with BOTs to receive fertility-
sparing surgery to maintain their fertility and achieve their
childbearing dreams. However, a recent concept concerning
about the clinical behavior of borderline ovarian tumor is that
it may be a precursor lesion of low-grade ovarian cancer.
Therefore, accurate diagnosis and complete staging proce-
dures seem to be important especially for patients who desire
to preserve their fertility function.17,18
Long-term follow-up of these patients is required because
recurrences can develop years after the primary treatment. For
women treated conservatively, special attention should be given
to the remaining ovary. Zanetta et al. evaluated the physical
examination, pelvic ultrasonography, and CA 125 levels to
determine the best modality for following patients after
conservative treatment of BOTs.19 It is advisable to observe
these patients every threemonths during the first twoyears, every
six months on the third to fifth year, and annually thereafter.
254 H.-W. Tsai et al. / Journal of the Chinese Medical Association 74 (2011) 250e254A limitation of this study is that surgical staging was not
considered beforehand in all cases. The data might therefore
be biased in this respect. Furthermore, our study was retro-
spective study with small sample sizes. Further studies using
a prospective design with emphasis on surgical staging are
required.
Fertility-sparing surgery is an acceptable and appropriate
option for women with BOTs who wish to preserve fertility.
The higher risk of local relapses is not associated with
decreased overall survival. The results here show that unilat-
eral salpingo-oophorectomy must be considered as the first
choice of conservative treatment. Ovarian cystectomy should
be reserved for patients with a previous history of unilateral
adnexectectomy or bilateral ovarian tumors, and is advocated
in incidental histologic discovery of BOTs. Whenever
possible, the treatment options for each possible operative
finding should be discussed thoroughly with the patient and
her family. Close follow-up is required.
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